Announcement • Jun 22
Ansell Limited Announces Chief Financial Officer Changes Ansell Limited announced the appointment of Erik Van den Enden as Chief Financial Officer, effective September 1, 2026. Mr. Van den Enden joined Ansell with nearly two decades of global finance leadership experience across the consumer goods, telecommunications, and infrastructure sectors. He held senior executive roles including Group CFO of Versuni, a global home-appliances company, and Group CFO and Head of M&A and Strategy at Telenet, a Belgian telecommunications and media group, where he led finance, procurement, supply chain, strategy and M&A teams and delivered major finance transformation initiatives. His earlier career also included senior finance leadership positions at Anheuser-Busch InBev, where he oversaw large-scale integration, transformation, treasury, and business planning activities. Mr. Van den Enden holds a master’s degree in electrotechnical engineering from KU Leuven and a Master in General Management from Vlerick Management School. Mr. Van den Enden will be based out of the Brussels, Belgium office. Mr. Van den Enden will be engaged via his sole purpose management service company in line with common Belgian senior management arrangements. As per the Company’s announcement on April 16, 2026, Mr. Fred Marx will continue to serve as Acting CFO until Mr. Van den Enden’s commencement. Announcement • Feb 16
Ansell Limited Announces Interim Dividend for the Six Months Ended December 31, 2025, Payable on March 13, 2026 Ansell Limited announced interim dividend of USD 0.26600000 per share for the six months ended December 31, 2025, payable on March 13, 2026. Record Date is February 24, 2026. Ex Date is February 23, 2026. Announcement • Feb 03
Ansell Introduces TouchNTuff 93-800: The First Disposable Glove with At Least 15 Minutes of Acetone Resistance Ansell Limited announced the launch of TouchNTuff 93-800, a breakthrough disposable glove designed to deliver at least 15 minutes of acetone resistance. This performance is fifteen times longer than standard nitrile disposable gloves currently available, offering a new level of safety for workers who handle aggressive solvents in demanding environments. Across aerospace, automotive, chemical manufacturing and maintenance, workers frequently encounter strong solvents that can quickly degrade traditional disposable gloves. This results in frequent glove changes, workflow disruption, and greater risk of chemical exposure. TouchNTuff 93-800 offers a reliable solution by providing documented acetone resistance in a comfortable disposable glove that maintains protection during prevent handling, wiping, cleaning and preparation tasks. TouchNTuff 93- 800 is powered by Ansell's MICROCHEM™? Chemical Barrier Technology and engineered with a multi-layer design of neoprene, nitrile and natural rubber latex. This design delivers EN ISO 374-1 Type A chemical resistance, including strong performance against ketones and other harsh solvents. Workers can complete tasks with greater consistency and safety without needing to switch between glove types throughout the day. The glove also provides certified abrasion and cut resistance under EN388 2110A, supporting durability during applications where precision and tactile control are essential. Its ergonomic construction enhances dexterity and reduces hand fatigue, while the high visibility orange color improves foreign object detection in controlled or high precision environments. Touch NTuff 93-800 also reflects Ansell's commitment to responsible innovation. The glove contains more than 60% bio-based carbon and is TUV certified, offering a more sustainable option for chemical protection without compromising performance. Announcement • Jan 13
Ansell Limited Announces Appointment of Ansell Limited as Independent Non-Executive Director , with Effect on March 1, 2026 Ansell Limited announced the appointment of Mr. Jonas Samuelson as an independent Non-Executive Director, with effect on 1 March 2026. Mr. Samuelson has also been invited to become a member of the Audit & Compliance Committee. Mr. Samuelson is an accomplished global executive with more than 30 years of experience across finance, operations, and general management in multinational industrial and consumer goods companies. He served as President & CEO of Electrolux Group from 20162025, having previously held senior leadership roles including Group CFO, COO, and CEO of Electrolux Major Appliances EMEA. Before Electrolux, he was CFO at Munters and spent over a decade at General Motors and Saab in a series of senior finance, commercial, and business development roles across Sweden and the United States. He holds board positions at Volvo Car AB (STO: VOLCAR-B) and Perrigo Company (NYSE: PRGO), as well as private companies Axel Johnson and Rosti Group AB. Mr. Samuelson holds a Master of Science in International Business Administration and Economics from Gothenburg School of Economics, Sweden. Announcement • Sep 25
Ansell Limited, Annual General Meeting, Oct 29, 2025 Ansell Limited, Annual General Meeting, Oct 29, 2025. Location: park hyatt melbourne, 1 parliament square, melbourne, victoria, Australia Announcement • Aug 25
Ansell Limited Declares Unfranked Ordinary Dividend for the Six Months Ended June 30, 2025, Payable on September 18, 2025 Ansell Limited declared unfranked ordinary dividend of USD 0.28000000 per share for the six months ended June 30, 2025. Record Date is September 01, 2025. Ex Date is August 29, 2025. Payment Date is September 18, 2025. Announcement • Mar 14
Ansell Limited Announces Chief Financial Officer Changes Ansell Limited announced the appointment of Brian Montgomery to the position of Chief Financial Officer (CFO), effective 14 April 2025. Mr. Montgomery is a senior finance and strategy executive. He most recently held the role of Chief Strategy Officer at
GE HealthCare, where he was responsible for driving the company's strategic goals and overseeing business development efforts. Prior to this, he served as acting CFO of GE HealthCare and held a variety of U.S. and European-based divisional finance, functional leadership, and business leadership roles where he led the development and implementation of strategic plans that drove both organic and inorganic value creation, including playing a key role in the spin-off of GE HealthCare from GE. Mr. Montgomery holds a Bachelor of Science in Industrial & Systems Engineering from Virginia Tech, with his functional finance experience grounded in his time in the GE Internal Audit program. Mr. Montgomery will be based out of the New Jersey, USA office. This appointment follows the Company's announcement on 14 October 2024 advising of the resignation of current CFO, Zubair Javeed. Mr. Javeed will step down as CFO on 14 March 2025, ahead of his formal departure from the Company at the end of the month. Fred Marx, currently Vice President - Group Corporate FP&A and Strategy, will take on the role of acting CFO for the period between 14 March 2025 and 14 April 2025. Announcement • Mar 03
Ansell Limited Expands Portfolio to Include Kimtech, Kleenguard and RightCycle Brands in North America and Europe Ansell Limited announced that its sales organisation will begin accepting Kimtech™ and KleenGuard™ orders and managing customer inquiries across North America and Europe. This marks the first significant commercial milestone following the strategic acquisition of Kimberly-Clark's Personal Protective Equipment (KCPPE) business last year and strengthens Ansell’s position as a global leader in safety solutions. With the addition of Kimtech and KleenGuard to Ansell’s market-leading portfolio of brands, Ansell offers an even broader range safety solutions to customers operating in laboratories, cleanrooms, and industrial manufacturing environments. As part of the North American and European portfolio expansion, Ansell also introduces two new capabilities: The RightCycle™ Program, a sustainable solution for the disposal of non-hazardous personal protective equipment (PPE) waste, and APEX™, a best-in-class approach to cleanroom customer change management and contamination control. The next milestone in the transition of this business will come in June 2025, when Ansell Latin America and Asia Pacific sales teams begin accepting orders for Kimtech and KleenGuard products. Announcement • Feb 10
Ansell Limited Declares Interim Dividend for the Six Months Ended December 31, 2024, Payable on March 6, 2025 Ansell Limited declared an interim dividend of USD 0.22200000 per share for the six months ended December 31, 2024, to be paid on March 6, 2025. The financial effect of this dividend has not been brought to account in the financial statements for the half year ended 31 December 2024 and will be recognized in subsequent financial reports. Record date for determining entitlements to the dividend February 17,2025. Ex- Date: February 14, 2025. Board Change • Dec 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Non Executive Director Debbie Goodin was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 14
Ansell Limited Announces Zubair Javeed Intention to Resign as Chief Financial Officer Ansell Limited announced that its Chief Financial Officer Zubair Javeed has given notice of his intention to resign from his position during the second quarter of calendar year 2025. Declared Dividend • Aug 22
Final dividend of US$0.22 announced Shareholders will receive a dividend of US$0.22. Ex-date: 26th August 2024 Payment date: 12th September 2024 Dividend yield will be 2.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (27% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Aug 21
Ansell Limited Announces Final Dividend for the Year Ended June 30, 2024 , Payable on September 12, 2024 Ansell Limited announced final dividend of USD 21.90 cents per share (unfranked) in respect of the year ended 30 June 2024 is payable on 12 September 2024 to shareholders registered on 27 August 2024. The financial effect of this dividend has not been brought to account in the audited FY24 Financial Statements and will be recognised in subsequent financial reports. There are no unissued shares under option at the date of this Report. Reported Earnings • Aug 21
Full year 2024 earnings released: EPS: US$0.59 (vs US$1.17 in FY 2023) Full year 2024 results: EPS: US$0.59 (down from US$1.17 in FY 2023). Revenue: US$1.62b (down 2.2% from FY 2023). Net income: US$76.5m (down 48% from FY 2023). Profit margin: 4.7% (down from 9.0% in FY 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Jul 02
Ansell Limited (ASX:ANN) completed the acquisition of Personal Protective Equipment business of Kimberly-Clark Corporation (NYSE:KMB). Ansell Limited (ASX:ANN) entered into a binding agreement to acquire Personal Protective Equipment business of Kimberly-Clark Corporation (NYSE:KMB) for $640 million on April 8, 2024. The acquisition was funded through $263 million fully underwritten institutional placement and a new $377 million Bridge Facility. For the 12 months ended 31 December 2023, Personal Protective Equipment business generated revenue of $272 million, EBITDA of $66 million and EBIT of $66 million. Personal Protective Equipment business reported implied EV/EBIT multiple of 9.7. The Acquisition is expected to complete in the first quarter of FY25, As of May 21, 2024 transaction expected to close on July 1, 2024. subject to satisfaction of antitrust approval and other customary closing conditions. J.P. Morgan Securities LLC and Centerview Partners LLC acted as financial advisor to Kimberly-Clark Corporation (NYSE:KMB). Goldman Sachs Australia Pty Ltd acted as financial advisor to Ansell Limited (ASX:ANN).Ansell Limited (ASX:ANN) completed the acquisition of Personal Protective Equipment business of Kimberly-Clark Corporation (NYSE:KMB) on July 2, 2024. New Risk • Apr 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (12% increase in shares outstanding). Announcement • Apr 09
Ansell Limited has filed a Follow-on Equity Offering in the amount of AUD 65 million. Ansell Limited has filed a Follow-on Equity Offering in the amount of AUD 65 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,895,323
Price\Range: AUD 22.45 Reported Earnings • Feb 21
First half 2024 earnings released: EPS: US$0.15 (vs US$0.51 in 1H 2023) First half 2024 results: EPS: US$0.15 (down from US$0.51 in 1H 2023). Revenue: US$784.9m (down 6.0% from 1H 2023). Net income: US$19.4m (down 70% from 1H 2023). Profit margin: 2.5% (down from 7.6% in 1H 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Feb 20
Ansell Limited Declares Dividend for the Six Months Ended December 31, 2023, Payable on March 14, 2024 Ansell Limited declared dividend of USD 0.16500000 per share for the six months ended December 31, 2023. Record date is February 27, 2024. Ex-date is February 26, 2024. Payment date is March 14, 2024. Announcement • Oct 25
Ansell Limited Provides Earnings Guidance for the Year 2024 Ansell Limited provided earnings guidance for the year 2024. For the period, the company expects statutory EPS to be in the range of $0.7 to $0.77. Announcement • Aug 15
Ansell Limited Declares Final Dividend for Year Ended 30 June 2023, Payable on 7 September 2023 Ansell Limited announced a final dividend of US 25.80 cents per share (unfranked) in respect of the year ended 30 June 2023 is payable on 7 September 2023 to shareholders registered on 21 August 2023. Dividend Reinvestment Plan election cut off date is 22 August 2023. Reported Earnings • Aug 14
Full year 2023 earnings released: EPS: US$1.18 (vs US$1.25 in FY 2022) Full year 2023 results: EPS: US$1.18 (down from US$1.25 in FY 2022). Revenue: US$1.66b (down 15% from FY 2022). Net income: US$148.3m (down 6.6% from FY 2022). Profit margin: 9.0% (up from 8.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jul 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €13.82, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 26x in the Medical Equipment industry in Germany. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €21.09 per share. Announcement • Jul 18
Ansell Limited Provides Earnings Guidance for the Full Year Ended 30 June 2023 and Fiscal Year 2024 Ansell Limited provided earnings guidance for the full year ended 30 June 2023 and fiscal year 2024. The company announced that based on initial consolidation of its full year results it expects to deliver statutory fiscal year 2023 EPS in the range of 117 US cents to 118 US cents. For the fiscal year 2024, Statutory EPS, including investment program costs, is expected to be in the range of 57 US cents to 77 US cents. Normalisation of incentive costs to reduce EBIT by $39 million versus fiscal year 2023. Buying Opportunity • Jul 17
Now 21% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be €20.78, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.2% over the last 3 years. Earnings per share has grown by 3.1%. For the next 3 years, revenue is forecast to grow by 2.8% per annum. Earnings is also forecast to grow by 6.4% per annum over the same time period. Announcement • Jun 13
Ansell Limited Announces Board Changes, Effective on 24 October 2023 13 June 2023 - Ansell Limited announced that John Bevan will retire as Chairman and a Non-Executive Director of Ansell, effective from 24 October 2023. Nigel Garrard, currently an independent Non-Executive Director, will replace Mr. Bevan as Chairman effective from this date. After joining the Ansell Board in 2012 as an independent Non-Executive Director, Mr. Bevan was appointed Deputy Chairman in 2017 and Chairman in 2019. Mr. Garrard joined the Ansell Board in March 2020. An experienced executive with a successful track record across the FMCG and Industrial/Manufacturing sectors, Mr. Garrard served a combined 20 years as CEO of three ASX-listed companies. As well as his role on Ansell's Board, he is currently Chairman of Flinders Port Holdings and McMahon Services Advisory Board and is a Non-Executive Director of CSR Limited and ALS Limited. Mr. Garrard will step down as Chair of the Human Resources Committee, effective on 24 October 2023. He will be succeeded as Chair of this Committee by independent and Non-Executive Director, Christine Yan. Reported Earnings • Feb 15
First half 2023 earnings released: EPS: US$0.51 (vs US$0.61 in 1H 2022) First half 2023 results: EPS: US$0.51 (down from US$0.61 in 1H 2022). Revenue: US$835.3m (down 17% from 1H 2022). Net income: US$63.9m (down 17% from 1H 2022). Profit margin: 7.6% (in line with 1H 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Feb 14
Ansell Limited Revises Earnings Guidance for the Fiscal Year 2023 Ansell Limited revised earnings guidance for the fiscal year 2023. The company is revising its fiscal year 2023 EPS guidance from the original range of USD 115 cents to USD 135 cents to a new range of USD 110 cents to USD 120 cents. Buying Opportunity • Jan 20
Now 20% undervalued Over the last 90 days, the stock is up 11%. The fair value is estimated to be €23.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 19%. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings is also forecast to grow by 5.8% per annum over the same time period. Recent Insider Transactions • Sep 06
Non-Executive Director recently bought €90k worth of stock On the 29th of August, Morten Falkenberg bought around 5k shares on-market at roughly €18.13 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €106k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 24
Full year 2022 earnings released: EPS: US$1.25 (vs US$1.92 in FY 2021) Full year 2022 results: EPS: US$1.25 (down from US$1.92 in FY 2021). Revenue: US$1.95b (down 3.7% from FY 2021). Net income: US$158.7m (down 36% from FY 2021). Profit margin: 8.1% (down from 12% in FY 2021). Over the next year, revenue is expected to shrink by 3.7% compared to a 7.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Aug 23
Ansell Limited to Report Fiscal Year 2023 Results on Aug 15, 2023 Ansell Limited announced that they will report fiscal year 2023 results on Aug 15, 2023 Reported Earnings • Feb 16
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: US$0.61 (down from US$0.82 in 1H 2021). Revenue: US$1.01b (up 7.6% from 1H 2021). Net income: US$77.2m (down 27% from 1H 2021). Profit margin: 7.6% (down from 11% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 4.6% compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €16.43, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 36x in the Medical Equipment industry in Germany. Total returns to shareholders of 17% over the past three years. Board Change • Dec 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Non-Executive Director Morten Falkenberg was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 24
Full year 2021 earnings released: EPS US$1.92 (vs US$1.22 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$2.03b (up 26% from FY 2020). Net income: US$246.7m (up 56% from FY 2020). Profit margin: 12% (up from 9.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 18
First half 2021 earnings released: EPS US$0.83 (vs US$0.50 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: US$937.8m (up 25% from 1H 2020). Net income: US$106.5m (up 62% from 1H 2020). Profit margin: 11% (up from 8.7% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 17% per year. Analyst Estimate Surprise Post Earnings • Feb 18
Revenue misses expectations Revenue missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 10%, compared to a 15% growth forecast for the Medical Equipment industry in Germany. Is New 90 Day High Low • Feb 12
New 90-day high: €25.00 The company is up 4.0% from its price of €24.00 on 13 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.70 per share. Recent Insider Transactions • Dec 11
Independent Non-Executive Director recently sold €159k worth of stock On the 8th of December, William Reilly sold around 8k shares on-market at roughly €21.22 per share. In the last 3 months, there was an even bigger sale from another insider worth €2.0m. Insiders have been net sellers, collectively disposing of €2.0m more than they bought in the last 12 months. Is New 90 Day High Low • Dec 04
New 90-day low: €21.60 The company is down 3.0% from its price of €22.20 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €21.91 per share. Recent Insider Transactions • Nov 14
MD, CEO & Executive Director recently sold €2.0m worth of stock On the 12th of November, Magnus Nicolin sold around 80k shares on-market at roughly €24.45 per share. This was the largest sale by an insider in the last 3 months. This was Magnus' only on-market trade for the last 12 months. Is New 90 Day High Low • Nov 04
New 90-day high: €25.40 The company is up 6.0% from its price of €24.00 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.55 per share. Announcement • Jul 30
Ansell Limited (ASX:ANN) completed the acquisition 50% stake in CAREPLUS (M) SDN. BHD from Careplus Group Berhad (KLSE:CAREPLS). Ansell Limited (ASX:ANN) entered into an agreement to acquire 50% stake in CAREPLUS (M) SDN. BHD from Careplus Group Berhad (KLSE:CAREPLS) on February 5, 2020. Under the terms, a total consideration of MYR 37 million will be paid which includes capital investment. Ansell Limited will acquire 14.5 million shares for approximately MYR 26.81 million payable in cash, subject to adjustments. The remaining MYR 10.19 million is capital investment. As on March 5, 2020, Careplus Group Bhd determined the final consideration for the acquisition as MYR 26.97 million and remaing as capital investment. The transaction is subject to approval from Careplus Group. The transaction is expected to close in March 2020. The transaction is expected to be EPS neutral and slightly EPS accretive.
Ansell Limited (ASX:ANN) completed the acquisition 50% stake in CAREPLUS (M) SDN. BHD from Careplus Group Berhad (KLSE:CAREPLS) on May 14, 2020.